Lyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" Series - Lyell Immunopharma (NASDAQ:LYEL)

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing...

Lyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" Series - Lyell Immunopharma (NASDAQ:LYEL)

SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will participate in the H.C. Wainwright "HCW@Home" Series taking place virtually on Wednesday, June 25, 2025, at 12:00 PM ET. The discussion will highlight the positive new clinical data re…

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable ...

LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with complete response remained in complete response at ≥…

LYL314 Yields High, Durable Response Rates in Later-Line LBCL Therapy

LYL314 elicited a complete response rate of 72%, with 71% lasting for 6 or more months in patients with large B-cell lymphoma in the third or later lines of therapy.

Lyell reports new clinical data from trial of large B-cell lymphoma therapy

Lyell Immunopharma has reported new clinical data from the Phase I/II clinical trial of CAR T-cell product candidate, LYL314.The post Lyell reports new clinical data from trial of large B-cell lymphoma therapy appeared first on Clinical Trials Arena.

Lyell’s lymphoma data for recently acquired CAR-T receive lukewarm reception on Wall Street

The company said Tuesday that its dual-targeting CD19/CD20 CAR-T called LYL314 induced 22 responses in a cohort of 25 patients with large B cell lymphoma, for an overall response rate of 88%. But investor response was tepid.